Mark M Moasser

List of Publications by Year
in descending order

25 papers	1,561 citations	686830 13 h-index	610482 24 g-index
26 all docs	26 docs citations	26 times ranked	2684 citing authors

#	Article	IF	Citations
1	Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Reports, 2022, 38, 110291.	2.9	7
2	Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Reports, 2022, 38, 110285.	2.9	7
3	Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Advances, 2022, 6, 2290-2302.	2.5	6
4	Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions. Cancer Research, 2022, 82, 2811-2820.	0.4	5
5	A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Research Communications, 2022, 2, 570-576.	0.7	1
6	Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3KÎ±/Î´ and HDAC. Journal of Investigative Dermatology, 2021, 141, 364-373.	0.3	17
7	Expression and purification of active human kinases using Pichia pastoris as a general-purpose host. Protein Expression and Purification, 2021, 179, 105780.	0.6	1
8	Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. Biochemical Pharmacology, 2021, 183, 114317.	2.0	13
9	Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain. Molecular Cancer Research, 2021, 19, 957-967.	1.5	9
10	The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Scientific Reports, 2021, 11, 9091.	1.6	20
11	Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. American Journal of Clinical and Experimental Urology, 2021, 9, 350-366.	0.4	0
12	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nature Communications, 2020, 11, 3584.	5.8	115
13	HER family in cancer progression: From discovery to 2020 and beyond. Advances in Cancer Research, 2020, 147, 109-160.	1.9	27
14	Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nature Cell Biology, 2019, 21, 778-790.	4.6	24
15	Targeting HER2 by Combination Therapies. Journal of Clinical Oncology, 2018, 36, 808-811.	0.8	13
16	A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Cell Reports, 2018, 25, 449-463.e4.	2.9	41
17	HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer Research, 2018, 78, 3645-3658.	0.4	85
18	CD318 is a ligand for CD6. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6912-E6921.	3.3	67

#	Article	IF	Citations
19	Effective treatment of HER2-amplified breast cancer by targeting HER3 and Î²1 integrin. Breast Cancer Research and Treatment, 2016, 155, 431-440.	1.1	15
20	Disentangling Multidimensional Spatio-Temporal Data into Their Common and Aberrant Responses. PLoS ONE, 2015, 10, e0121607.	1.1	1
21	A TORC2â€“Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Molecular Cancer Therapeutics, 2015, 14, 2805-2817.	1.9	4
22	Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1472-1479.	0.8	31
23	Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver. Science Translational Medicine, 2010, 2, 16ra7.	5.8	154
24	Improved tumor vascular function following highâ€dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of Magnetic Resonance Imaging, 2007, 26, 1618-1625.	1.9	23
25	Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature, 2007, 445, 437-441.	13.7	853